Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement

Clinical Infectious Diseases

Volumn 36, Issue 6, 2003, Pages 759-765

  McGovern, Paul C ^a,b   Lautenbach, Ebbing ^a   Brennan, Patrick J ^a   Lustig, Robert A ^a   Fishman, Neil O ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CEFAZOLIN; CEFTRIAXONE; CLINDAMYCIN; NAFCILLIN; SULBACTAM; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL INFECTION; BRAIN ABSCESS; BRAIN TUMOR; CANDIDA PARAPSILOSIS; CANDIDIASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRANIOTOMY; DEPRESSION; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; GLIOMA; GRAM POSITIVE BACTERIUM; HUMAN; IMPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK FACTOR; SURGICAL INFECTION;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG IMPLANTS; GLIOMA; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0037443855     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/368082     Document Type: Article

References (41)

1. Black PM. Brain tumors. N Engl J Med 1991; 324:1555-64.
2. Gliadel wafers for treatment of brain tumors. Med Lett Drugs Ther 1998; 40:92.
3. Brem H, Piantadosi 8, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery system by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345:1008-12.
4. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41:44-9.
5. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 2000; 53:220-4.
6. Subach BR, Witham TF, Kondziolka D, et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999; 45:17-23.
7. Bertin ML, Mani A, Barnett G, et al. Risk factors for surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosurea (BCNU) Gliadel wafer implantation for glioblastoma [abstract]. Infect Control Hosp Epidemiol 2000; 21:144.
8. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20:250-78.
9. Culver DH, Horan TC, Gaynes RP, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. Am J Med 1991; 91:152S-7S.
10. Kleinbaum DG, Kupper LL, Morgenstem H. Epidemiologic research principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719.
12. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
13. Tenney JH, Vlahov D, Salcman M, Ducker TB. Wide variation in risk of wound infection following clean neurosurgery: implications for perioperative antibiotic prophylaxis. J Neurosurg 1985; 62:243-7.
14. Brown EM. Antimicrobial prophylaxis in neurosurgery. J Antimicrob Chemother 1993; 31(Suppl B):49-63.
15. Blomstedt GC. Craniotomy infections. Neurosurg Clin North Am 1992; 3:375-85.
16. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report: data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429-48.
17. Young RF, Lawner PM. Perioperative antibiotic prophylaxis for prevention of postoperative neurosurgical infections. J Neurosurg 1987; 66:701-5.
18. Blomstedt GC, Kyttä J. Results of a randomized trial of vancomycin prophylaxis in craniotomy. J Neurosurg 1988; 69:216-20.
19. van Ek B, Dijkmans BAC, van Dulken H, van Furth R. Antibiotic prophylaxis in craniotomy: a prospective double-blind placebo-controlled study. Scand J Infect Dis 1988; 20:633-9.
20. Bullock R, van Dellen JR, Ketelbey W, Reinach SG. A double-blind placebo-controlled trial of perioperative prophylactic antibiotics for elective neurosurgery. J Neurosurg 1988; 69:687-91.
21. Djindjian M, Lepresle E, Homs JB. Antibiotic prophylaxis during prolonged clean neurosurgery. J Neurosurg 1990; 73:383-6.
22. Pons VG, Denlinger SL, Guglielmo BJ, et al. Ceftizoxime versus vancomycin and gentamicin in neurosurgical prophylaxis: a randomized, prospective, blinded clinical study. Neurosurgery 1993; 33:416-23.
23. Barker FG II. Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 1994; 35:484-92.
24. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther 1999; 41:75-9.
25. Wilhelm MP, Estes L. Vancomycin. Mayo Clin Proc 1999; 74:928-35.
26. Fekety R. Vancomycin, teicoplanin, and the streptogramins: quinupristin and dalfopristin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:382-92.
27. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:274-91.
28. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999; 74:187-95.
29. Kernodle DS, Kaiser AB. Postoperative infections and antimicrobial prophylaxis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:3177-91.
30. Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. Infect Control Hosp Epidemiol 1994; 15:463-71.
31. Korinek AM. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. Neurosurgery 1997; 41:1073-81.
32. Agarwal SK, Marshall GD Jr. Stress effects on immunity and its application to clinical immunology. Clin Exp Allergy 2001; 31:25-31.
33. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 1995; 345:99-103.
34. Schindler BA. Stress, affective disorders, and immune function. Med Clin North Am 1985; 69:585-97.
35. Irwin M. Immune correlates of depression. In: Dantzer R, Wollmann EE, Yirmiya R, eds. Cytokines, stress, and depression. New York: Kluwer Academic Publishers, 1999:1-24.
36. Sheridan JF, Dobbs C, Brown D, et al. Psychoneuroimmunology. Clin Microbiol Rev 1994; 7:200-12.
37. Emori TG, Edwards JR, Horan TC, et al. Risk factors for surgical site infection following craniotomy operation reported to the National Nosocomial Infections Surveillance System [abstract]. Infect Control Hosp Epidemiol 2000; 21:144.
38. Mollman HD, Haines SJ. Risk factors for postoperative neurosurgical wound infections, a case-control study. J Neurosurg 1986; 64:902-6.
39. Centers for Disease Control and Infection. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996; 24:380-8.
40. Horan TC. Surgical site infection (SSI) risk stratum rates: what they are and how to compare them using aggregated data from the NNIS system poster [poster 158]. In: Programs and abstracts of the Association for Professionals in Infection Control (APIC) conference (Orlando, Florida). Washington, DC: APIC, 1993.
41. Horan TC, Gaynes RP, Culver D, et al. Development of predictive risk factors for nosocomial surgical site infections (SSIs) [abstract]. Infect Control Hosp Epidemiol 1994; 15:46.